Mechanism of Action of St John’s Wort in Depression (original) (raw)

• Rosenthal N. St John’s wort: the herbal way to feeling good. New York: Harper Collins Publishers, 1998
  Google Scholar
• Bombardelli E, Morazzoni P. Hypericum perforatum. Fitoterapia 1995; 66: 43–68
  CAS Google Scholar
• Lohse MJ, Müller-Oerlinghausen B. Psychopharmaka. In: Schwabe U, Paffrath D, editors. Arzneiverordnungreport 2000. Berlin: Springer Verlag, 2000: 581–7
  Google Scholar
• Schulz V. Incidence and clinical relevance of the interactions and side effects of Hypericum preparations. Phytomedicine 2001; 8(2): 152–60
  PubMed CAS Google Scholar
• National Center for Complementary and Alternative Medicine. St John’s wort fact sheet (publication Z-02). Bethesda: National Institutes of Health, 1999
  Google Scholar
• Brenner R, Azbel V, Madhusoodanan S, et al. Comparison of an extract of Hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study. Clin Ther 2000; 22(4): 411–9
  PubMed CAS Google Scholar
• Harrer G, Schulz V. Clinical investigation of the antidepressant effectiveness of Hypericum. J Geriatr Psychiatry Neurol 1994; 7Suppl. 1: S6–8
  PubMed Google Scholar
• Philipp M, Kohnen R, Hiller K. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. BMJ 1999; 319: 1534–8
  PubMed CAS Google Scholar
• Schrader E. Equivalence of St John’s wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol 2000; 5(2): 61–8
  Google Scholar
• Volz HP. Controlled clinical trials of Hypericum extracts in depressed patients: an overview. Pharmacopsychiatry 1997; 30Suppl. 2: 72–6
  PubMed Google Scholar
• Woelk H. Comparison of St John’s wort and imipramine for treating depression: randomised controlled trial. BMJ 2000; 321(7260): 536–9
  PubMed CAS Google Scholar
• Linde K, Ramirez G, Mulrow C. St John’s wort in depression-and overview and meta-analysis of randomised clinical trials. BMJ 1996; 313: 253–8
  PubMed CAS Google Scholar
• Wheatly D. Hypericum extract: potential in the treatment of depression. CNS Drugs 1998; 9: 431–40
  Google Scholar
• Vorbach EU, Arnoldt KH, Hübner WD. Efficacy and tolerability of St John’s wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10. Pharmacopsychiatry 1997; 30Suppl. 2: 77–80
  Google Scholar
• Laakmann G, Schule C, Baghai T, et al. St John’s wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 1998; 31Suppl. 1: 54–9
  PubMed CAS Google Scholar
• Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St John’s wort in major depression. JAMA 2001; 285(15): 1978–86
  PubMed CAS Google Scholar
• Effect of Hypericum perforatum (St John’s wort) in major depressive disorder. JAMA 2002; 287 (14): 1807–14
• Nahrstedt A. Antidepressant constituents of Hypericum perforatum. In: Chrubasik S, Roufogalis BD, editors. Herbal medicinal products for the treatment of pain. Lismore: Southern Cross University Press, 2000: 144–53
  Google Scholar
• Nahrstedt A, Butterweck V. Biologically active and other chemical constituents of the herb of Hypericum perforatum L. Pharmacopsychiatry 1997; 30Suppl. 2: 129–34
  PubMed CAS Google Scholar
• Butterweck V, Wall A, Lieflaender-Wulf U, et al. Effects of the total extract and fractions of Hypericum perforatum in animal assays for antidepressant activity. Pharmacopsychiatry 1997; 30Suppl. 2: 117–24
  PubMed CAS Google Scholar
• Jürgenliemk G, Nahrstedt A. Phenolic compounds from Hypericum perforatum. Planta Med 2002; 68: 88–91
  PubMed Google Scholar
• Chatterjee SS, Bhattacharya S, Wonnemann M, et al. Hyperforin as a possible antidepressant component of Hypericum extracts. Life Sci 1998; 63: 499–510
  PubMed CAS Google Scholar
• Singer A, Wonnemann M, Müller W. Hyperforin, a major antidepressant constituent of St John’s wort, inhibits serotonin uptake by elevating free intracellular Na+. J Pharmacol Exp Ther 1999; 290: 1363–8
  PubMed CAS Google Scholar
• Müller WE, Singer A, Wonnemann M. Hyperforin-antidepressant activity by a novel mechanism of action. Pharmacopsychiatry 2001; 34Suppl. 1: S98–S102
  PubMed Google Scholar
• Wonnemann M, Singer A, Siebert B, et al. Evaluation of synaptosomal uptake inhibition of most relevant constituents of St John’s wort. Pharmacopsychiatry 2001; 41Suppl. 1: S148–S51
  Google Scholar
• Butterweck V, Petereit F, Winterhoff H, et al. Solubilized hypericin and pseudohypericin from Hypericum perforatum exert antidepressant activity in the forced swimming test. Planta Med 1998; 64: 291–4
  PubMed CAS Google Scholar
• Butterweck V, Winterhoff H, Herkenham M. St John’s wort, hypericin, and imipramine: a comparative analysis of mRNA levels in brain areas involved in HPA axis control following short-term and long-term administration in normal and stressed rats. Mol Psychiatry 2001; 6: 547–64
  PubMed CAS Google Scholar
• Butterweck V, Nahrstedt A, Evans J, et al. In vitro receptor screening of pure constituents of St John’s wort reveals novel interaction with a number of GPCR’s. Psychopharmacology 2002; 162: 193–202
  PubMed CAS Google Scholar
• Butterweck V, Jürgenliemk G, Nahrstedt A, et al. Flavonoids from Hypericum perforatum show antidepressant activity in the forced swimming test. Planta Med 2000; 66: 3–6
  PubMed CAS Google Scholar
• Calapai G, Crupi A, Firenzuoli F, et al. Effects of Hypericum perforatum on levels of 5-hydroxytryptamine, noradrenaline and dopamine in the cortex, diencephalon and brainstem of the rat. J Pharm Pharmacol 1999; 51: 723–8
  PubMed CAS Google Scholar
• Suzuki O, Katsumata Y, Oya M. Inhibition of monoamine oxidase by hypericin. Planta Med 1984; 50: 272–4
  PubMed CAS Google Scholar
• Demisch L, Hölzl J, Gollnik B. Identification of selective MAO-type-A inhibitors in Hypericum perforatum L. Pharmacopsychiatry 1989; 22: 194–6
  Google Scholar
• Sparenberg BL, Demisch J, Hölzl J. Untersuchungen über die antidepressiven Wirkstoffe von Johanniskraut. Pharm Ztg Wiss 1993; 138: 239–54
  Google Scholar
• Bladt S, Wagner H. Inhibition of MAO by fractions and constituents of Hypericum extract. J Geriatr Psychiatry 1994; 154: 125–34
  Google Scholar
• Thiede HM, Walper A. Inhibition of MAO and COMT by Hypericum extracts and hypericin. J Geriatr Psychiatry Neurol 1994; 7: S54–S6
  PubMed Google Scholar
• Cott JM. In vitro binding and enzyme inhibition by Hypericum perforatum extract. Pharmacopsychiatry 1997; 30Suppl. 2: 108–12
  PubMed CAS Google Scholar
• Müller W, Rolli M, Schäfer C, et al. Effects of Hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry 1997; 30Suppl. 2: 102–7
  PubMed Google Scholar
• Cracchiolo C. Pharmacology of St John’s wort: botanical and chemical aspects. Sci Rev Alt Med 1998; 2: 29–35
  Google Scholar
• Müller WE, Schäfer C. Johanniskraut: in-vitro Studie über Hypericum-extrakt (LI 160), hypericin und kämpferol als antidepressiva. Dtsch Apoth Ztg 1996; 136: 17–24
  Google Scholar
• Amara SG, Kuhar MJ. Neurotransmitter transporters: recent progress. Annu Rev Neurosci 1993; 16: 73–93
  PubMed CAS Google Scholar
• Shaskan EG, Snyder SH. Kinetics of serotonin accumulation into slices from rat brain: relationship to catecholamine uptake. J Pharmacol Exp Ther 1970; 175: 404–18
  PubMed CAS Google Scholar
• Snyder SH. Putative neurotransmitters in the brain: selective neuronal uptake, subcellular localization, and interactions with centrally acting drugs. Biol Psychiatry 1970; 2: 367–89
  PubMed CAS Google Scholar
• Fuller RW, Wong DT. Serotonin uptake and serotonin uptake inhibition. Ann N Y Acad Sci 1990; 600: 68–78
  PubMed CAS Google Scholar
• Horn AS, Coyle JT, Snyder SH. Catecholamine uptake by synaptosomes from rat brain: structure-activity relationships of drugs with differential effects on dopamine and norepinephrine neurons. Mol Pharmacol 1971; 7: 66–80
  PubMed CAS Google Scholar
• Bourin M, Baker GB. The future of antidepressants. Biomed Pharmacother 1996; 50: 7–12
  PubMed CAS Google Scholar
• Richelson E. Synaptic effects of antidepressants. J Clin Psychopharmacol 1996; 16Suppl. 2: 1S–7S
  PubMed CAS Google Scholar
• Gobbi M, Dalla Valle F, Ciapparelli C, et al. Hypericum perforatum L. extract does not inhibit 5-HT transporter in rat brain cortex. Naunyn Schmiedebergs Arch Pharmacol 1999; 360: 262–9
  PubMed CAS Google Scholar
• Müller WE, Singer A, Wonnemann M, et al. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of Hypericum extract. Pharmacopsychiatry 1998; 31Suppl. 1: 16–21
  PubMed Google Scholar
• Neary JT, Whittemore SR, Bu Y, et al. Biochemical mechanisms of action of Hypericum LI 160 in glial and neuronal cells: inhibition of neurotransmitter uptake and stimulation of extracellular signal regulated protein kinase. Pharmacopsychiatry 2001; 34Suppl. 1: S103–S7
  PubMed CAS Google Scholar
• Perovic S, Müller WE. Pharmacological profile of Hypericum extract. Arzneimittel Forschung 1995; 45: 1145–8
  PubMed CAS Google Scholar
• Kientsch U, Bürgi S, Ruedeberg C, et al. St John’s wort extract ZE 117 (Hypericum perforatum) inhibits norepinephrine and serotonin uptake into rat brain slices and reduces β-adrenoceptor numbers on cultured rat brain cells. Pharmacopsychiatry 2001; 34Suppl. 1: S56–60
  PubMed CAS Google Scholar
• Jensen AG, Hansen SH, Nielsen EO. Adhyperforin as a contributor to the effect of Hypericum perforatum L. in biochemical models of antidepressant activity. Life Sci 2001; 68: 1593–605
  PubMed CAS Google Scholar
• Raffa RB. Screen of receptor and uptake-site activity of hypericin component of St John’s wort reveals S-receptor binding. Life Sci 1998; 62(16): 265–70
  Google Scholar
• Haslam E. Natural polyphenols (vegetable tannins) as drugs: possible modes of action. J Nat Prod 1996; 59: 205–15
  PubMed CAS Google Scholar
• Buchholzer ML, Dvorak C, Chatterjee SS, et al. Dual modulation of striatal acetylcholine release by hyperforin, a constituent of St John’s wort. J Pharmacol Exp Ther 2002; 301(2): 714–9
  PubMed CAS Google Scholar
• Wonnemann M, Singer A, Müller WE. Inhibition of synaptosomal uptake of 3H-L-glutamate and 3H-GABA by hyperforin, a major constituent of St John’s wort: the role of amiloride sensitive sodium conductive pathways. Neuropsy-chopharmacology 2000; 23(2): 188–97
  CAS Google Scholar
• Fisunov A, Lozovaya N, Tsintsadze T, et al. Hyperforin modulates gating of P-type Ca2+ current in cerebellar Purkinje neurons. Eur J Physiol 2000; 440: 427–34
  CAS Google Scholar
• Krishtal O, Lozovaya N, Fisunov A, et al. Modulation of ion channels in rat neurons by the constituents of Hypericum perforatum. Pharmacopsychiatry 2001; 34Suppl. 1: S74–82
  PubMed CAS Google Scholar
• Chatterjee S, Filippov V, Lishko P, et al. Hyperforin attenuates various ionic conductance mechanisms in the isolated hippocampal neurons of the rat. Life Sci 1999; 65(22): 2395–405
  PubMed CAS Google Scholar
• Biber A, Fischer H, Römer A, et al. Oral bioavailability of hyperforin from Hypericum extracts in rats and human volunteers. Pharmacopsychiatry 1998; 31Suppl. 1: 36–43
  PubMed CAS Google Scholar
• Yu PH. Effect of the Hypericum perforatum extract on serotonin turnover in the mouse brain. Pharmacopsychiatry 2000; 33: 60–5
  PubMed CAS Google Scholar
• Serdarevic N, Eckert GP, Müller WE. The effects of extracts of St John’s wort and kava kava on brain neurotransmitter levels in the mouse. Pharmacopsychiatry 2001; 34Suppl. 1: S134–S6
  PubMed CAS Google Scholar
• Fornal CA, Metzler CW, Mirescu C, et al. Effects of standardized extracts of St John’s wort on the single-unit activity of serotonergic dorsal raphe neurons in awake cats: comparisons with fluoxetine and sertraline. Neuropsychopharmacology 2001; 25(6): 858–70
  PubMed CAS Google Scholar
• Di Matteo V, Di Giovanni G, Di Mascio M, et al. Effect of acute administration of Hypericum-CO2 extract on dopamine and serotonin release in the rat central nervous system. Pharmacopsychiatry 2000; 33: 14–8
  PubMed Google Scholar
• Rommelspacher H, Siemanowitz B, Mannel M. Acute and chronic actions of a dry methanolic extract of Hypericum perforatum and a hyperforin-rich extract on dopaminergic and serotonergic neurons in rat nucleus accumbens. Pharmacopsychiatry 2001; 34Suppl. 1: S119–S26
  PubMed CAS Google Scholar
• Franklin M, Chi JD, Mannel M, et al. Acute effects of LI 160 (extract of Hypericum perforatum, St John’s wort) and two of its constituents on neuroendocrine responses in the rat. J Psychopharmacol 2000; 14(4): 360–3
  PubMed CAS Google Scholar
• Kaehler ST, Sinner C, Chatterjee SS, et al. Hyperforin enhances the extracellular concentrations of catecholamines, serotonin and glutamate in the rat locus coeruleus. Neurosci Lett 1999; 262: 199–202
  PubMed CAS Google Scholar
• Philippu A. In vivo neurotransmitter release in the locus coeruleus-effects of hyperforin, inescapable shock and fear. Pharmacopsychiatry 2001; 34Suppl. 1: S111–S5
  PubMed CAS Google Scholar
• Brady LS, Whitfield HJ, Fox RJ, et al. Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase and mineralocorticoid receptor gene expression in rat brain. J Clin Invest 1991; 87: 831–7
  PubMed CAS Google Scholar
• Brady LS, Gold PW, Herkenham M, et al. The antidepressant fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. Brain Res 1992; 572: 117–25
  PubMed CAS Google Scholar
• Butterweck V, Böckers T, Körte B, et al. Long-term effects of St John’s wort and hypericin on monoamine levels in rat hypothalamus and hippocampus. Brain Res 2002; 930: 21–9
  PubMed CAS Google Scholar
• Franklin M, Cowen PJ. Researching the antidepressant actions of Hypericum perforatum (St John’s wort) in animals and man. Pharmacopsychiatry 2001; 34Suppl. 1: S29–37
  PubMed CAS Google Scholar
• Winterhoff H, Butterweck V, Nahrstedt A, et al. Pharmakologische Untersuchungen zur antidepressiven Wirkung von Hypericum perforatum L. In: Loew D, Rietbrock N, editors. Phytopharmaka in forschung und klinischer anwendung. Darmstadt: Steinkopff Verlag, 1995: 39–56
  Google Scholar
• Butterweck V, Korte B, Winterhoff H. Pharmacological and endocrine effects of Hypericum perforatum and hypericin after repeated treatment. Pharmacospsychiatry 2001; 34Suppl. 1: S2–7
  CAS Google Scholar
• Franklin M, Chi J, McGavin C, et al. Neuroendocrine evidence for dopaminergic actions of Hypericum extract (LI 160) in healthy volunteers. Biol Psychiatry 1999; 46: 581–4
  PubMed CAS Google Scholar
• Tuomisto J, Mannisto P. Neurotransmitter regulation of anterior pituitary hormones. Pharmacol Rev 1985; 37(3): 249–311
  PubMed CAS Google Scholar
• Charney DS, Menkes DB, Heninger GR. Receptor sensitivity and the mechanism of action of antidepressant treatment: implications for the etiology and therapy of depression. Arch Gen Psychiatry 1981; 38: 1160–80
  PubMed CAS Google Scholar
• Heninger GR, Charney DS. Mechanism of action of antidepressant treatments: implications for the etiology and treatment of depressive disorders. In: Meltzer H, editor. Psychopharmacology: the third generation in progress. New York: Raven Press, 1987: 535–44
  Google Scholar
• Sulser F, Vetulani J, Mobley P. Mode of action of antidepressant drugs. Biochem Pharmacol 1978; 27: 257–61
  PubMed CAS Google Scholar
• Banerjee SP, Kung LS, Riggi SJ, et al. Development of β-adrenergic receptor subsensitivity by antidepressants. Nature 1977; 268: 455–6
  PubMed CAS Google Scholar
• Vetulani J, Sulser F. Action of antidepressant treatments reduces reactivity of noradrenergic cAMP-generating system in limbic forebrain. Nature 1975; 257: 495–6
  PubMed CAS Google Scholar
• Meltzer HY. Role of serotonin in depression. Ann N Y Acad Sci 1990; 600: 486–99
  PubMed CAS Google Scholar
• Teufel-Mayer R, Gleitz J. Effects of long-term administration of Hypericum extracts on the affinity and density of the central serotonergic 5-HTia and 5-HT2A receptors. Pharmacopsychiatry 1997; 30Suppl. 2: 113–6
  PubMed CAS Google Scholar
• Butterweck V. Beitrag zur pharmakologie und wirkstofffindung von Hypericum perforatum L. Münster: Institut für pharmazeutische Biologie und Phytochemie, Westfälische Wilhelms-Universität, 1997
  Google Scholar
• Baker G, Greenshaw A. Effects of long-term administration of antidepressants and neuroleptics on receptors in the central nervous system. Cell Mol Neurobiol 1989; 9: 1–44
  PubMed CAS Google Scholar
• Leonard BE. Mechanisms of action of antidepressants. CNS Drugs 1995; 4Suppl. 1: 1–12
  CAS Google Scholar
• Leonard BE. The comparative pharmacological properties of selective serotonin re-uptake inhibitors in animals. In: Feigh-ner JP, Boyer WF, editors. Selective serotonin re-uptake inhib-itors: advances in basic research and clinical practice. Chiches-ter: John Wiley and Sons, 1996: 35–62
  Google Scholar
• Watanabe Y, Sakai R, McEwen B, et al. Stress and antidepressant effects on hippocampal and cortical 5-HTIA and 5-HT2 receptors and transport sites for serotonin. Brain Res 1993; 615: 87–94
  PubMed CAS Google Scholar
• Lopez J, Chalmers D, Little K, et al. Regulation of serotoninl A, glucocorticoid and mineralocorticoid receptor in rat brain and human hippocampus: implications for the neurobiology of depression. Biol Psychiatry 1998; 43: 547–73
  PubMed CAS Google Scholar
• Briley M, Moret C. Neurobiological mechanisms involved in antidepressant therapies. Clin Neuropharmacol 1993; 16: 387–400
  PubMed CAS Google Scholar
• Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994; 15: 220–6
  PubMed CAS Google Scholar
• Eison A, Yocca FD, Gianutsos G. Effect of chronic administration of antidepressant drugs on 5-HT2 mediated behaviour in the rat following noradrenergic or serotonergic denervation. J Neural Trans 1991; 84: 19–32
  CAS Google Scholar
• Goodnough DB, Baker GB. 5-hydroxytryptamine 2 and β-adrenergic receptor regulation in rat brain following chronic treatment with desipramine and fluoxetine alone and in combination. J Neurochem 1994; 62: 2262–8
  PubMed CAS Google Scholar
• Hrdina PD, Vu TB. Chronic fluoxetine treatment upregulates 5-HT uptake sites and 5-HT2 receptors in the rat brain: an autoradiographic study. Synapse 1993; 14: 324–31
  PubMed CAS Google Scholar
• Stahl S. 5HT1A receptors and pharmacotherapy: is serotonin receptor down-regulation linked to the mechanism of action of antidepressant drugs? Psychopharmacol Bull 1994; 30: 39–43
  PubMed CAS Google Scholar
• Simmen U, Burkard W, Berger K, et al. Extracts and constituents of Hypericum perforatum inhibit the binding of various ligands to recombinant receptors expressed with the Semliki Forest virus system. J Recept Signal Transduct Res 1999; 19: 59–74
  PubMed CAS Google Scholar
• Simmen U, Higelin J, Berger-Büter K, et al. Neurochemical studies with St John’s wort in vitro. Pharmacopsychiatry 2001; 34Suppl. 1: S137–S42
  PubMed CAS Google Scholar
• Gobbi M, Moia M, Pirona L, et al. In vitro binding studies with two Hypericum perforatum extracts - hyperforin, hypericin and biapigenin - on 5-HT6, 5-HT7, GABAA/benzodiazepine, sigma, NPY-Y1/Y2 receptors and dopamine transporters. Pharmacopsychiatry 2001; 34Suppl. 1: S45–S8
  PubMed CAS Google Scholar
• Chatterjee SS, Nöldner M, Koch E, et al. Antidepressant activity of Hypericum perforatum and hyperforin: the neglected possibility. Pharmacopsychiatry 1998; 31Suppl. 1: 7–15
  PubMed CAS Google Scholar
• Baureithel KH, Buter KB, Engesser A, et al. Inhibition of benzodiazepine binding in vitro by amentoflavone, a constituent of various species of Hypericum. Pharm Acta Helv 1997; 72(3): 153–7
  PubMed CAS Google Scholar
• Nielsen M, Frokjaer S, Braestrup C. High affinity of the naturally-occurring biflavonoid, amentoflavon, to brain benzodiazepine receptors in vitro. Biochem Pharmacol 1988; 37(17): 3285–7
  PubMed CAS Google Scholar
• Kroeze WK, Roth BL. The molecular biology of serotonin receptors: therapeutic implications for the interface of mood and psychosis. Biol Psychiatry 1998; 44: 1128–42
  PubMed CAS Google Scholar
• Roth BL, Meltzer HY, Khan N. Binding of typical and atypical antipsychotic drugs to multiple neurotransmitter receptors. Adv Pharmacol 1998; 42: 482–5
  PubMed CAS Google Scholar
• Thiebot MH, Martin P, Puech AJ. Animal behavioural studies in the evaluation of antidepressant drugs. Br J Psychiatry Suppl 1992; 160(15): 44–50
  Google Scholar
• Porsolt R, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977; 266: 730–2
  PubMed CAS Google Scholar
• Overmier JB, Seligman MEP. Effects of inescapable shock upon subsequent escape and avoidance learning. J Comp Physiol Psychol 1967; 78: 340–3
  Google Scholar
• Porsolt RD. Behavioural despair. In: Enna SJ, Malick JB, Richelson E, editors. Antidepressants: neurochemical, behavioural and clinical perspectives. New York: Raven Press, 1981: 121–39
  Google Scholar
• Betin C, De Feudis FV, Blavet N, etal. Further characterization of the behavioural despair in mice: positive effects of convulsants. Physiol Behav 1982; 28: 307–11
  PubMed CAS Google Scholar
• Browne RG. Effects of antidepressants and anticholinergics in a mouse “behavioural despair” test. Eur J Pharmacol 1979; 58: 331–4
  PubMed CAS Google Scholar
• Schlechter MD, Chance WT. Non-specificity of “behavioural despair” as an animal model of depression. Eur J Pharmacol 1979; 60: 139–42
  Google Scholar
• Wallach MD, Hedley LR. The effects of antihistamines in a modified behavioural despair test. Commun Psychopharmacol 1979; 3: 35–9
  PubMed CAS Google Scholar
• Kitada Y, Miyauchi T, Satoh A, et al. Effects of antidepressants in the rat forced swimming test. Eur J Pharmacol 1981; 72: 145–52
  PubMed CAS Google Scholar
• Porsolt R, Anton G, Blavet N, et al. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 1978; 47: 379–91
  PubMed CAS Google Scholar
• Cryan JF, Markou A, Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002; 23(5): 238–45
  PubMed CAS Google Scholar
• De Vry J, Maurel S, Schreiber R, et al. Comparison of Hypericum extracts with imipramine and fluoxetine in animal models of depression and alcoholism. Eur Neuropsychopharmacol 1999; 9: 461–8
  Google Scholar
• Özturk Y. Testing the antidepressant effects of Hypericum species on animal models. Pharmacopsychiatry 1997; 30Suppl. 2: 125–8
  PubMed Google Scholar
• Panocka I, Perfumi M, Angeletti S, et al. Effects of Hypericum perforatum extract on ethanol intake, and on behavioural despair: a search for the neurochemical systems involved. Pharmacol Biochem Behav 2000; 66(1): 105–11
  PubMed CAS Google Scholar
• Maier SF, Seligman MEP. Learned helplessness: theory and evidence. J Exp Psychol 1976; 1: 3–46
  Google Scholar
• Garber J, Miller WR, Seaman SF. Learned helpless, stress and the depressive disorders. In: Depue RA, editor. The psychobiology of depressive disorders: implications for the effects of stress. New York: Academic Press, 1979: 335–63
  Google Scholar
• Dorworthy TR, Overmeier JB. On “learned helplessness”: the therapeutic effects of electroconvulsive shock. Physiol Behav 1977; 4: 355–8
  Google Scholar
• Martin P, Soubrie P, Simon P. The effect of monoamine oxidase inhibitors compared with classical tricyclic antidepressants on learned helplessness paradigm. Prog Neuropsychopharmacol Biol Psychiatry 1987; 11: 1–7
  PubMed CAS Google Scholar
• Martin P, Soubrie P, Puech AJ. Reversal of helpless behaviour by serotonin uptake blockers in rats. Psychopharmacology 1990; 101: 403–7
  PubMed CAS Google Scholar
• Sherman AD, Sacquinte JL, Petty F. Specificity of the learned helplessness model of depression. Pharmacol Biochem Behav 1982; 16: 449–54
  PubMed CAS Google Scholar
• Willner P. The validity of animal models of depression. Psychopharmacology 1984; 83: 1–16
  PubMed CAS Google Scholar
• Willner P. Animal models of depression: an overview. Pharmacol Ther 1990; 45: 425–55
  PubMed CAS Google Scholar
• Gambrana C, Ghiglieri O, Tolu P, et al. Efficacy of an Hypericum perforatum (St John’s wort) extract in preventing and reverting a condition of escape deficit in rats. Neuropsycho-pharmacology 1999; 21(2): 247–54
  Google Scholar
• Gambrana C, Tolu PL, Masi F, et al. A study of the antidepressant activity of Hypericum perforatum on animal models. Pharmacopsychiatry 2001; 34Suppl. 1: S42–S4
  Google Scholar
• Holsboer F, Spengler D, Heuser I. The role of corticotropin-releasing hormone in the pathogenesis of Cushing’s disease, anorexia nervosa, alcoholism, affective disorders and dementia. Prog Brain Res 1992; 93: 385–417
  PubMed CAS Google Scholar
• Holsboer F, Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr Rev 1996; 17: 187–205
  PubMed CAS Google Scholar
• Ansseau M. Hormonal disturbances in depression. In: Honig A, Van Praag HM, editors. Depression: neurobiological, psycho-pathological and therapeutic advances. Chichester: John Wiley & Sons, 1997: 235–50
  Google Scholar
• Vetulani J, Nalepa I. Antidepressants: past, present and future. Eur J Pharmacol 2000; 405: 351–63
  PubMed CAS Google Scholar
• Gold P, Goodwin F, Chrousos G. Clinical and biochemical manifestations of depression: relation to the neurobiology of stress. N Engl J Med 1988; 319: 348–53
  PubMed CAS Google Scholar
• Raadsher F, Hoogendijk W, Stam F, et al. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 1994; 60: 436–44
  Google Scholar
• Barden N, Reul J, Holsboer F. Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenal axis? Trends Neurosci 1995; 18: 6–11
  PubMed CAS Google Scholar
• Pepin M, Govindan M, Barden N. Increased glucocorticoid receptor gene promoter activity after antidepressant treatment. Mol Pharmacol 1992; 41: 1016–22
  PubMed CAS Google Scholar
• Herman J. In situ hybridization analysis of vasopressin gene transcription in the paraventricular and supraoptic nuclei of the rat: regulation by stress and glucocorticoids. J Comp Neurol 1995; 363: 15–27
  PubMed CAS Google Scholar
• Mamalaki E, Kvetnansky R, Brady L, et al. Repeated immobilization stress alters tyrosine hydroxylase, corticotropin-releasing hormone and corticosteroid receptor messenger ribonucleic acid levels in rat brain. J Neuroendocrinol 1992; 4(6): 690–5
  Google Scholar
• Sawchenko P, Brown E, Chan R, et al. The paraventricular nucleus of the hypothalamus and the functional neuroanatomy of visceromotor responses to stress. Prog Brain Res 1996; 107: 201–22
  PubMed CAS Google Scholar
• Fuchs E, Kramer M, Hermes B, et al. Psychological stress in tree shrews: clomipramine counteracts behavioural and endocrine changes. Pharmacol Biochem Behav 1996; 54(1): 219–28
  PubMed CAS Google Scholar
• Plaznik A, Palejko W, Stefanski R, et al. Open field behaviour of rats reared in different social conditions: the effects of stress and imipramine. Pol J Pharmacol 1993; 45(3): 243–52
  PubMed CAS Google Scholar
• Thiele B, Brink I, Ploch M. Modulation of cytokine expression by Hypericum extract. J Geriatr Psychiatry Neurol 1994; 7: S60–S2
  PubMed Google Scholar
• Fiebich BL, Höllig A, Lieb K. Inhibition of substance P-induced cytokine synthesis by St John’s wort extracts. Pharmacopsychiatry 2001; 34Suppl. 1: S26–S8
  PubMed CAS Google Scholar
• Maubach KA, Ruoniak NM, Kramer MS, et al. Novel strategies for pharmacotherapy of depression. Curr Opin Chem Biol 1999; 3: 481–8
  PubMed CAS Google Scholar